Clinical trials with reno-vascular end points in patients with diabetes: Changing the scenario over the past 20 years

Tomasz J Block; Mark E Cooper

doi:10.1016/j.lpm.2023.104178

Clinical trials with reno-vascular end points in patients with diabetes: Changing the scenario over the past 20 years

Presse Med. 2023 Mar;52(1):104178. doi: 10.1016/j.lpm.2023.104178. Epub 2023 Sep 30.

Authors

Tomasz J Block¹, Mark E Cooper²

Affiliations

¹ Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia.
² Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia. Electronic address: Mark.Cooper@monash.edu.

PMID: 37783423
DOI: 10.1016/j.lpm.2023.104178

Abstract

Major clinical advances over the last 20 years in the area of diabetic kidney disease (DKD) have been confirmed in large seminal clinical trials. These findings add to the previously identified benefits resulting from intensive glucose and blood pressure control therapies. Furthermore, newer glucose lowering treatments such as SGLT2 inhibitors and GLP-1 agonists appear very promising and are likely to transform the management and outlook of DKD over the next decade. In addition, novel mineralocorticoid receptor antagonists and a recently reported trial with an endothelin receptor blocker also have the potential to change clinical practice.

Keywords: Diabetic complications; Diabetic kidney disease; Diabetic nephropathy; Prevention; Renoprotection; Therapeutic targets.

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Diabetic Nephropathies* / drug therapy
Glucose
Humans
Kidney
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors
Glucose